Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 2008	Column: In the pipeline Problems develop when there are too few workhorse reactions, which may well generate compounds that are too similar to each other. Are we at that stage now?
Chemistry World October 2010	Column: In the pipeline Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
Chemistry World September 2008 Derek Lowe	Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful'
Chemistry World October 2009	Column: In the pipeline Derek Lowe discusses the problem of leaning too heavily on favorite reactions
Chemistry World August 2007 Derek Lowe	Opinion: In the Pipeline Process chemists just don't get the credit they deserve.
Chemistry World June 2008 Sarah Houlton	Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success
Chemistry World November 2006 Yfke Hager	Careers: Heartfelt Chemistry After working in New Zealand, medicinal chemistry tempted Ashley Jarvis back to the UK. He now works in his dream field.
Bio-IT World September 9, 2002 John P. Helfrich	Data Management in High-Throughput Screening The high-throughput drug discovery field requires an optimal IT platform.
Chemistry World April 2011	Molecular Obesity is Weighing Down Drug Discovery Medicinal chemistry's quest for potent drug candidates has resulted in molecules that are too large and too lipophilic for their own good.
Chemistry World February 2009 Derek Lowe	Column: In the pipeline How important is it to have the best equipped lab? One group holds that there's little effect at all, that good scientists can do good work with whatever's at hand.
Bio-IT World July 11, 2002 Kevin Davies	Counting the Cost of Drug Discovery Much of the trouble ensnaring the drug industry is blamed on the exorbitant cost of drug discovery. Tangible proof that the bio-IT revolution will economize drug discovery is emerging, but there is still a long way to go.
Chemistry World March 2008 Derek Lowe	Column: In the Pipeline How to revive some lost chemistry techniques.
Bio-IT World November 2006 Kevin Davies	Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities.
Chemistry World July 30, 2015 Derek Lowe	A precision instrument? How much do medicinal chemists and their biology colleagues really trust each other's data? In the end, they have to, because drug discovery is a team sport.
Chemistry World November 25, 2014 James Urquhart	Nanomolar chemistry enables 1500 experiments in a single day Chemists have conducted over 1500 chemistry experiments in under a day thanks to a miniaturized, high throughput automation platform they developed for identifying how synthetic molecules react under various conditions.
Bio-IT World April 2007 Vicki Glaser	Software Solutions for Medicinal Chemistry Driven by advances in chemical synthesis, instrumentation, and high-throughput and high-content screening technology, medicinal chemistry's transition from an art to a science is benefiting from a wealth of new software products, spanning both bio- and cheminformatics.
Chemistry World August 2009 Derek Lowe	Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder
Chemistry World July 2008 Kevin Rogers	What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril
Bio-IT World March 2006 Robert M. Frederickson	Integration, Robotics, and Automation The integration of instruments and technology is a key concept driving the development of advanced life-sciences laboratory automation. More sophisticated robotics are also increasingly being integrated into automated systems.
Bio-IT World January 13, 2003 John Dodge	Talent Fuels Drug Pipeline in Swiss Time The functional genomics group has emerged as a critical link in the drug discovery chain at Novartis Pharmaceuticals Corp. While it employs a multidisciplinary approach to drug discovery, the four-year-old group's goals could not be simpler: Find novel drug targets.
Chemistry World August 2010	Column: In the pipeline Derek Lowe reminisces about lost laboratory techniques and wonders which will be next to go
Chemistry World December 2007 Derek Lowe	Column: In the Pipeline The challenge of biologics.
The Motley Fool August 17, 2010 Brian Orelli	Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.
Chemistry World December 2008	Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project.
Chemistry World June 2011	Column: In the pipeline Chemists are human. Humans are hierarchical. Therefore...well, therefore, you'll find a number of different roles and levels for scientists in a drug company's labs. Here's a rough ordering, from least experienced to most.
CIO October 15, 2001 Stephanie Overby	Drug Companies on speed The marriage of IT and medical research may be just what traditional pharmaceutical companies need to survive in an increasingly competitive field. Learn how IT is bringing the pharmaceutical industry into the information age...
The Motley Fool November 26, 2007 Brian Lawler	Biogen Plays Deal Maker Biogen Idec signs a drug development deal with Swiss-based Neurimmune Therapeutics worth up to $380 million. Investors, take note.
Bio-IT World November 14, 2003 Malorye Branca	Genomics Provides the Kick Inside New tools and business structures show signs of plumping early-stage pipelines.
Chemistry World June 20, 2013 Jim Al-Khalili	Change: the only constant Today, there is much interest in a wide range of biological phenomena that may have a quantum origin, from our sense of smell to photosynthesis and mutations in DNA.
The Motley Fool February 8, 2005 Charly Travers	Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company
The Motley Fool January 12, 2005 Charly Travers	Alzheimer's Drug on the Horizon? Myriad Genetics' innovative technology creates an investment opportunity.
Chemistry World December 2006 Derek Lowe	Opinion: In the Pipeline A look at the story behind the growing investment by western companies in medicinal chemistry research in China.
Chemistry World April 2007 Derek Lowe	Opinion: In the Pipeline Natural products can be ridiculously complicated. The sheer difficulty of the enterprise is traditionally what made pharmaceutical companies hire people who had worked in total synthesis. But, is total synthesis research still worth the effort?
Bio-IT World May 7, 2002 Anthony Strattner	Molecular Machining Blending nanotechnology with bioengineering, researchers at engeneOS use genomic information as engineerable parts to build biomolecules.
Chemistry World July 2010	Column: In the pipeline Derek Lowe ponders the possibility of phosphatase inhibitors
Pharmaceutical Executive May 1, 2001	On Tour with Merck's Robots Merck's HTS robots move assay plates through the screening process.
Bio-IT World November 12, 2002 Michael Goldman	A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico?
Chemistry World November 27, 2013 Derek Lowe	Rolling boulders uphill A lot of preclinical projects don't even get off the ground, and many that do still never deliver anything to the development groups.
Chemistry World November 28, 2013	Put the chemistry back in medicinal chemistry Today, synthetic skill is valued and appreciated much less in medicinal chemistry than in chemical development, though it is equally important for both. Much of the blame lies with the mismeasurement of productivity.
Chemistry World March 2010 Derek Lowe	Column: In the pipeline The author takes a tour of the 'storage graveyard' where instruments that aren't useful or are too fiddly are doomed to end up
Chemistry World September 9, 2011 James Mitchell Crow	High-throughput catalyst screening for the masses Using nothing more than the standard chemistry lab equipment, researchers in the US have successfully turned the discovery of new catalytic reactions into a high-throughput process.
Chemistry World March 2011	Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Chemistry World April 2009 Derek Lowe	Column: In the pipeline The author considers the problems of addressing drug development out of sequence
Chemistry World August 1, 2012 Patrick Walter	Phenomenal Olympic science legacy (or is that sustainability?) What do you do with a lab set up solely to catch Olympic drug cheats once the games are over? In the case of the London 2012 games, the answer is to turn it into a state of the art analytical lab.
Reactive Reports Issue 74 David Bradley	Reactive Profile--Noel O'Boyle Interview with a Postdoctoral Research Associate in the Development Group working on drug discovery, protein-ligand docking, cheminformatics, QSAR, and computational chemistry.
Bio-IT World October 2005 Robert M. Frederickson	Nanoflow Enhances LC Devices New flow control systems save time while offering higher precision and sensitivity that are key to better comparative proteomic data coming out of liquid chromatography-mass spectronomy applications as well as more traditional clinical and diagnostic analyses.
Bio-IT World November 12, 2002 James Golden	The Business of Bioinformatics The industry has reached an interesting crossroads. As an academic branch of learning, bioinformatics remains mostly what it always was, a cross-disciplinary endeavor between computer science and molecular biology. But bioinformatics as a money-making proposition has different criteria for success.
Chemistry World March 2012	Lead-oriented synthesis Ian Churcher and Alan Nadin call for the development of more robust synthetic tools to improve small molecule survival rates in the perilous journey from lead to drug
Chemistry World June 2010	Column: In the pipeline Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
HHMI Bulletin Nov 2011 Sarah C.P. Williams.	Carolyn Bertozzi: Changed Expectations Chemists trained in biology were once a rarity -- now they're becoming the norm.